Neuralink received the “innovative” label from the Food and EU drug administration (FDA) for its “Brindsight” device, which restores communication to people with serious speech disabilities, according to Elon Musk’s brain implants company on Thursday in an X publication.
The device would help people affected by amyotrophic lateral sclerosis (ELA), stroke, spinal cord injury, cerebral palsy, multiple sclerosis and other neurological conditions, according to the company.
Read also: Second Neuralink patient uses its brain implant to design 3D objects
FDA will make available to patients and professionals device ‘blindsight’
The innovative devices program of the health regulator aims to provide patients with health professionals timely access to medical devices, accelerating development, evaluation and review, according to their website.
The FDA and Neuralink did not immediately respond to requests for Reuters comments.
With Reuters information
Inspy, discover and share. Follow us and find what you are looking for on our Instagram!
